CG
HRTX icon

Cutler Group’s Heron Therapeutics HRTX Stock Holding History

Cutler Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,800
Closed -$15K – 5255
2022
Q1 		$15K Buy
+1,800
New +$13.2K ﹤0.01% 3285
2020
Q4 		– Sell
-12,900
Closed -$16K – 5083
2020
Q3 		$16K Buy
12,900
+2,100
+19% +$32.8K ﹤0.01% 2635
2020
Q2 		$31K Sell
10,800
-14,200
-57% -$233K ﹤0.01% 2074
2020
Q1 		$41K Buy
+25,000
New +$470K ﹤0.01% 1845
2019
Q4 		– Sell
-3,500
Closed -$3K – 4233
2019
Q3 		$3K Sell
3,500
-6,500
-65% -$120K ﹤0.01% 3300
2019
Q2 		$4K Buy
+10,000
New +$200K ﹤0.01% 3225
2018
Q3 		– Sell
-3,700
Closed -$2K – 4354
2018
Q2 		$2K Sell
3,700
-13,000
-78% -$414K ﹤0.01% 3572
2018
Q1 		$7K Buy
+16,700
New +$379K ﹤0.01% 3045
2017
Q3 		– Sell
-6,200
Closed -$8K – 6195
2017
Q2 		$8K Buy
6,200
+3,400
+121% +$49.2K ﹤0.01% 4365
2017
Q1 		$2K Sell
2,800
-47,200
-94% -$653K ﹤0.01% 5438
2016
Q4 		$158K Buy
50,000
+14,300
+40% +$224K 0.01% 1499
2016
Q3 		$86K Buy
35,700
+28,900
+425% +$536K ﹤0.01% 1935
2016
Q2 		$3K Sell
6,800
-18,500
-73% -$361K ﹤0.01% 5364
2016
Q1 		$83K Buy
25,300
+20,700
+450% +$408K 0.01% 1794
2015
Q4 		$20K Buy
+4,600
New +$123K ﹤0.01% 3416

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Cutler Group's HRTX Position: Q1 2024 in Review

Cutler Group reduced its Heron Therapeutics (HRTX) stake by 3.4% in Q1 2024, selling an estimated $251 and leaving 2,800 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #1432.

Cutler Group first reported a position in HRTX in Q4 2015 and has held it in 32 quarters since. The position peaked at $739K in Q4 2016. 161 funds tracked by Wall St. Rank hold HRTX as of Q1 2024.

  • Cutler Group held 2,800 shares of Heron Therapeutics worth $7K as of Q1 2024.
  • Cutler Group sold 100 Heron Therapeutics shares in Q1 2024, an estimated $251.
  • Heron Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1432 holding.
  • Cutler Group first reported a position in Heron Therapeutics in Q4 2015 and has held it in 32 quarters since.
  • Cutler Group's Heron Therapeutics position peaked at $739K in Q4 2016.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.